X hits on this document

Word document

Teratogen Update: Reproductive Risks of Leflunomide (Arava™); a Pyrimidine Synthesis - page 21 / 21

56 views

0 shares

0 downloads

0 comments

21 / 21

Protection and Measurements. The Effects of Pre- and Postconception Exposure to Radiation, April 2-3, 1997, Arlington, Virginia. Teratology 59:182-204.

Davis JP, Cain GA. et al. 1996. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry, 35:1270-73.

Herrmann M, Grangou CG, Kirschbaum B. 1997. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21 pathways. Arth Rheum, 40:S 177.

Silva HT, Slauson SD. et al. 1998. Inhibition of dihydroorotate dehydrogenase (DHO-DH) is the molecular mechanism of immunosuppression by malonitrilomides (MNAs) in vivo. Intl Soc for Heart and Lung Transplantation, Abstract, 18th annual meeting.

Wilson, JG, Brent RL and Jordan HC. 1953. Differentiation as a determinant of the reaction of rat embryos to x-irradiation.  Proc. Soc. Exp. Biol. Med. 82:67-70, 1953; also appeared in U.S.A.E.C.D. U.R.-243.

Document info
Document views56
Page views56
Page last viewedWed Dec 07 21:16:39 UTC 2016
Pages21
Paragraphs114
Words5821

Comments